TScan Therapeutics Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company with a market capitalization of $139.57 million, is poised at a critical juncture in its development of innovative ...

Location: Stars at Night B2 & B3 (Ballroom Level, Henry B. González Convention Center) A copy of the presentation materials will be added to the “Events and Presentations” section of the Company’s ...

From what we can see, insiders were net buyers in TScan Therapeutics, Inc.'s (NASDAQ:TCRX ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. While ...

WALTHAM, Mass.--(BUSINESS WIRE)--TScan Therapeutics, a biopharmaceutical company focused on the development of T cell receptor (TCR) therapies which reprogram a patient’s own T cells to recognize ...

WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...

The latest price target for TScan Therapeutics (NASDAQ:TCRX) was reported by HC Wainwright & Co. on November 13, 2025. The analyst firm set a price target for $7.00 expecting TCRX to rise to within 12 ...

TScan Therapeutics, Inc. (NASDAQ:TCRX) shares are trading higher in the premarket session on Thursday. The firm announced a significant financing deal, entering into a securities purchase agreement ...

Ratings for TScan Therapeutics (NASDAQ:TCRX) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...

Looking at TScan Therapeutics, Inc.'s (NASDAQ:TCRX ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders ...

To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) No dose-limiting toxicities ...

Phase 1 umbrella trial of TSC-100 and TSC-101 active in five sites; on track to enroll first two cohorts in 1H 2023 with interim data by end of 2023 Advancing solid tumor program with development of ...

Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up ...